文献速递真实世界研究与卫生经济流行病学与生物统计

新型结核病疫苗在低收入和中等收入国家的成本与成本效果:一项建模研究

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
PubMed 文献 · PLoS Med · 2023-01-24

研究构建流行病学与经济模型,覆盖105个低收入和中等收入国家,评估引入新型结核病疫苗的未来成本、成本节约与成本效果。在疫苗价格4.60美元及1倍人均GDP成本效果阈值下,青少年/成人疫苗接种在105国中的64国具成本效果,社会视角下为73国具成本效果、58国可节约成本。

要点

  • 青少年/成人疫苗接种在64/105个低收入和中等收入国家具成本效果(卫生系统视角)。
  • 社会视角下青少年/成人疫苗接种在73/105国具成本效果,58/105国可节约成本。

核心结论

  • 结核病疫苗接种在大多数低收入和中等收入国家将具有高度影响力和成本效果。
  • 未来需要进一步努力推动新型结核病疫苗的研发、采纳和实施。

研究设计与样本

  • 研究构建了流行病学与经济模型系统,校准至105个低收入和中等收入国家的人口学、流行病学和卫生服务数据。
  • 在每个国家比较多种疫苗引入情景与「无新疫苗」反事实情景下的结核病相关结局未来可能病程。
  • 疫苗情景考虑2种疫苗产品特征(1种针对婴儿,1种针对青少年/成人),均假设可预防进展为活动性结核病。
  • 关键经济投入来自全球卫生成本联盟、世界卫生组织(WHO)患者成本调查和已发表文献。
  • 基础案例假设疫苗价格为4.60美元,采用1倍人均国内生产总值(GDP)的成本效果阈值(均在敏感性分析中变化)。

主要发现

  • 疫苗引入估计需要大量近期资源投入,但可被未来避免结核病负担带来的成本节约所抵消。
  • 从卫生系统视角,青少年/成人疫苗接种在105个低收入和中等收入国家中的64个具成本效果。
  • 从社会视角(包括生产力收益和避免的患者成本),青少年/成人疫苗接种预计在105国中的73国具成本效果,在58国可节约成本,包括96%的结核病高负担国家。

关键数值与推荐

  • 基础案例疫苗价格:4.60美元。
  • 成本效果阈值:1倍人均GDP。
  • 卫生系统视角下青少年/成人疫苗接种在64/105个低收入和中等收入国家具成本效果。
  • 社会视角下青少年/成人疫苗接种在73/105国具成本效果,在58/105国可节约成本,包括96%的结核病高负担国家。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据可得性有限,需要假设和外推,可能遗漏国家层面重要的流行病学和成本异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies. METHODS AND FINDINGS: We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a "no-new-vaccine" counterfactual. Vaccine scenarios considered 2 vaccine product profiles (1 targeted at infants, 1 at adolescents/adults), both assumed to prevent progression to active TB. Key economic inputs were derived from the Global Health Cost Consortium, World Health Organization (WHO) patient cost surveys, and the published literature. We estimated the incremental impact of vaccine introduction for a range of health and economic outcomes. In the base-case, we assumed a vaccine price of $4.60 and used a 1× per-capita gross domestic product (GDP) cost-effectiveness threshold (both varied in sensitivity analyses). Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. From a health system perspective, adolescent/adult vaccination was cost-effective in 64 of 105 LMICs. From a societal perspective (including productivity gains and averted patient costs), adolescent/adult vaccination was projected to be cost-effective in 73 of 105 LMICs and cost-saving in 58 of 105 LMICs, including 96% of countries with higher TB burden. When considering the monetized value of health gains, we estimated that introduction of an adolescent/adult vaccine could produce $283 to 474 billion in economic benefits by 2050. Limited data availability required assumptions and extrapolations that may omit important country-level heterogeneity in epidemiology and costs. CONCLUSIONS: TB vaccination would be highly impactful and cost-effective in most LMICs. Further efforts are needed for future development, adoption, and implementation of novel TB vaccines.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Portnoy A, Clark RA, Quaife M, et al. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. PLoS Med. 2023. PMID: 36693081. doi:10.1371/journal.pmed.1004155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。